183 related articles for article (PubMed ID: 26336931)
1. Selective Ability of Some CANTAB Battery Test Measures to Detect Cognitive Response to a Single Dose of Donepezil in Alzheimer Disease.
Kuzmickienė J; Kaubrys G
Med Sci Monit; 2015 Aug; 21():2572-82. PubMed ID: 26336931
[TBL] [Abstract][Full Text] [Related]
2. Cognitive Results of CANTAB Tests and Their Change Due to the First Dose of Donepezil May Predict Treatment Efficacy in Alzheimer Disease.
Kuzmickienė J; Kaubrys G
Med Sci Monit; 2015 Dec; 21():3887-99. PubMed ID: 26656642
[TBL] [Abstract][Full Text] [Related]
3. Specific Features of Executive Dysfunction in Alzheimer-Type Mild Dementia Based on Computerized Cambridge Neuropsychological Test Automated Battery (CANTAB) Test Results.
Kuzmickienė J; Kaubrys G
Med Sci Monit; 2016 Oct; 22():3605-3613. PubMed ID: 27717954
[TBL] [Abstract][Full Text] [Related]
4. Cognitive predictors of donepezil therapy response in Alzheimer disease.
Saumier D; Murtha S; Bergman H; Phillips N; Whitehead V; Chertkow H
Dement Geriatr Cogn Disord; 2007; 24(1):28-35. PubMed ID: 17495473
[TBL] [Abstract][Full Text] [Related]
5. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting.
Tariot PN; Cummings JL; Katz IR; Mintzer J; Perdomo CA; Schwam EM; Whalen E
J Am Geriatr Soc; 2001 Dec; 49(12):1590-9. PubMed ID: 11843990
[TBL] [Abstract][Full Text] [Related]
6. Distinctive Effect of Donepezil Treatment on P300 and N200 Subcomponents of Auditory Event-Related Evoked Potentials in Alzheimer Disease Patients.
Vaitkevičius A; Kaubrys G; Audronytė E
Med Sci Monit; 2015 Jul; 21():1920-7. PubMed ID: 26138001
[TBL] [Abstract][Full Text] [Related]
7. Effect of donepezil on cognition in severe Alzheimer's disease: a pooled data analysis.
Cummings J; Jones R; Wilkinson D; Lopez O; Gauthier S; Waldemar G; Zhang R; Xu Y; Sun Y; Richardson S; Mackell J
J Alzheimers Dis; 2010; 21(3):843-51. PubMed ID: 20634594
[TBL] [Abstract][Full Text] [Related]
8. Donepezil preserves cognition and global function in patients with severe Alzheimer disease.
Black SE; Doody R; Li H; McRae T; Jambor KM; Xu Y; Sun Y; Perdomo CA; Richardson S
Neurology; 2007 Jul; 69(5):459-69. PubMed ID: 17664405
[TBL] [Abstract][Full Text] [Related]
9. Methodological improvements in quantifying cognitive change in clinical trials: an example with single-dose administration of donepezil.
Pietrzak RH; Maruff P; Snyder PJ
J Nutr Health Aging; 2009 Mar; 13(3):268-73. PubMed ID: 19262966
[TBL] [Abstract][Full Text] [Related]
10. Concentration of donepezil to the cognitive response in Alzheimer disease.
Yang YH; Chen CH; Chou MC; Li CH; Liu CK; Chen SH
J Clin Psychopharmacol; 2013 Jun; 33(3):351-5. PubMed ID: 23609381
[TBL] [Abstract][Full Text] [Related]
11. Donepezil provides greater benefits in mild compared to moderate Alzheimer's disease: implications for early diagnosis and treatment.
Molinuevo JL; Berthier ML; Rami L
Arch Gerontol Geriatr; 2011; 52(1):18-22. PubMed ID: 19948364
[TBL] [Abstract][Full Text] [Related]
12. Do the Cambridge Neuropsychological Test Automated Battery episodic memory measures discriminate amnestic mild cognitive impairment?
Juncos-Rabadán O; Pereiro AX; Facal D; Reboredo A; Lojo-Seoane C
Int J Geriatr Psychiatry; 2014 Jun; 29(6):602-9. PubMed ID: 24150876
[TBL] [Abstract][Full Text] [Related]
13. Additional donepezil treatment for patients with geriatric depression who exhibit cognitive deficit during treatment for depression.
Inoue J; Hoshino R; Nojima H; Ishida W; Okamoto N
Psychogeriatrics; 2016 Jan; 16(1):54-61. PubMed ID: 25919986
[TBL] [Abstract][Full Text] [Related]
14. Cognitive stimulation therapy for Alzheimer's disease: the effect of cognitive stimulation therapy on the progression of mild Alzheimer's disease in patients treated with donepezil.
Matsuda O
Int Psychogeriatr; 2007 Apr; 19(2):241-52. PubMed ID: 17005066
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo-controlled trial.
Feldman H; Gauthier S; Hecker J; Vellas B; Xu Y; Ieni JR; Schwam EM;
Int J Geriatr Psychiatry; 2005 Jun; 20(6):559-69. PubMed ID: 15920715
[TBL] [Abstract][Full Text] [Related]
16. Apolipoprotein E epsilon4 allele differentiates the clinical response to donepezil in Alzheimer's disease.
Bizzarro A; Marra C; Acciarri A; Valenza A; Tiziano FD; Brahe C; Masullo C
Dement Geriatr Cogn Disord; 2005; 20(4):254-61. PubMed ID: 16103669
[TBL] [Abstract][Full Text] [Related]
17. Psychometric evaluation of ADAS-Cog and NTB for measuring drug response.
Karin A; Hannesdottir K; Jaeger J; Annas P; Segerdahl M; Karlsson P; Sjögren N; von Rosen T; Miller F
Acta Neurol Scand; 2014 Feb; 129(2):114-22. PubMed ID: 23763450
[TBL] [Abstract][Full Text] [Related]
18. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial.
Tariot PN; Farlow MR; Grossberg GT; Graham SM; McDonald S; Gergel I;
JAMA; 2004 Jan; 291(3):317-24. PubMed ID: 14734594
[TBL] [Abstract][Full Text] [Related]
19. Evidence of practice effect in CANTAB spatial working memory test in a cohort of patients with mild cognitive impairment.
Cacciamani F; Salvadori N; Eusebi P; Lisetti V; Luchetti E; Calabresi P; Parnetti L
Appl Neuropsychol Adult; 2018; 25(3):237-248. PubMed ID: 28631988
[TBL] [Abstract][Full Text] [Related]
20. Differential efficacy of treatment with acetylcholinesterase inhibitors in patients with mild and moderate Alzheimer's disease over a 6-month period.
López-Pousa S; Turon-Estrada A; Garre-Olmo J; Pericot-Nierga I; Lozano-Gallego M; Vilalta-Franch M; Hernández-Ferràndiz M; Morante-Muñoz V; Isern-Vila A; Gelada-Batlle E; Majó-Llopart J
Dement Geriatr Cogn Disord; 2005; 19(4):189-95. PubMed ID: 15677866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
